Differential Antinociception Induced by Spinally Administered Endomorphin-1 and Endomorphin-2 in the Mouse

  1. Masahiro Ohsawa1,
  2. Hirokazu Mizoguchi1,
  3. Minoru Narita1,2,
  4. Hiroshi Nagase3,
  5. John P. Kampine1 and
  6. Leon F. Tseng1
  1. 1Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin (M.O., H.M., M.N., J.P.K., L.F.T.); 2Department of Toxicology, Hoshi University, Shinagawa-Ku, Japan (M.N.); and3Pharmaceutical Research Laboratory, Toray Industries Inc., Kamakura, Japan (H.N.)
  1. Leon F. Tseng, Ph.D., Department of Anesthesiology, MEB-M4308 Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI. E-mail: ltseng{at}mcw.edu
 
Next Section

Abstract

We have previously demonstrated that the antinociception induced by either endomorphin-1 or endomorphin-2 given supraspinally is mediated by the stimulation of μ-opioid receptors. However, the antinociception induced by endomorphin-2 given supraspinally contains additional components, which are mediated by the spinal release of dynorphin A (1–17) acting on κ-opioid receptors and the spinal release of [Met5]enkephalin acting on δ2-opioid receptors in the spinal cord. The present studies were performed to determine whether there are any differential effects on the tail-flick inhibition induced by endomorphin-1 and endomorphin-2 given intrathecally (i.t.) in mice. Endomorphin-1 or endomorphin-2 given i.t. inhibited the tail-flick response in a dose-dependent manner. The tail-flick inhibition induced by endomorphin-1 was blocked by i.t. pretreatment with μ-opioid receptor antagonistd-Phe-Cys-Tyr-d-Try-Orn-Thr-Pen-Thr-NH2(CTOP), but not κ-opioid receptor antagonist nor-binaltorphimine (nor-BNI), δ1-opioid receptor antagonist 7-benzylidene naltrexamine (BNTX), or δ2-opioid receptor antagonist naltriben (NTB). In contrast, the tail-flick inhibition induced by endomorphin-2 given i.t. was blocked by i.t. pretreatment with CTOP or nor-BNI, but not BNTX or NTB. Intrathecal pretreatment with antiserum against dynorphin A (1–17), but not antiserum against [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin, blocked the tail-flick inhibition induced by i.t.-administered endomorphin-2. None of these antisera attenuated the i.t.-administered endomorphin-1-induced tail-flick inhibition. It is concluded that the tail-flick inhibition induced by endomorphin-1 and endomorphin-2 given spinally is mediated by the stimulation of μ-opioid receptors. However, the tail-flick inhibition induced by spinally injected endomorphin-2 contains an additional component, which is mediated by the spinal release of dynorphin A (1–17) acting on κ-opioid receptors in the spinal cord. We propose that there are at least two different subtypes of μ-opioid receptors for endomorphin-1 and endomorphin-2 to produce antinociception in the spinal cord.

Two new peptides, endomorphin-1 and endomorphin-2, have been recently isolated from mammalian brain. These two peptides activate μ-opioid receptors with high affinity and selectivity, raising the possibility that they are two endogenous μ-opioid receptor ligands (Zadina et al., 1997). In receptor binding assays, both endomorphin-1 and endomorphin-2 bind to opioid μ1- and μ2-receptor sites potently (Goldberg et al., 1998). Neither compound has appreciable affinities for opioid δ- and κ1-receptors. Endomorphins were found in the regions of the brain and spinal cord, which are also rich in μ-opioid receptors (Martin-Schild et al., 1997, 1998; Zadina et al., 1997;Pierce et al., 1998; Schreff et al., 1998). Endomorphin-1 is more widely and more densely distributed throughout the brain than endomorphin-2, whereas endomorphin-2 is more prevalent in the spinal cord than endomorphin-1. The greatest density of endomorphin-2 fibers is located in superficial laminae of the spinal dorsal horn and the nucleus of the spinal trigeminal tract (Martin-Schild et al., 1999). Since endomorphin-2 immunoreactivity is diminished by the dorsal rhizotomy and colocalized with calcitonin gene-related peptide or Substance P, it seems likely that endomorphin-2 is present in the primary sensory afferent neurons (Martin-Schild et al., 1997, 1998;Pierce et al., 1998).

In behavioral experiments, intrathecal (i.t.) or i.c.v. injection of endomorphin-1 or endomorphin-2 produces potent analgesia, which is blocked by the pretreatment with the μ-opioid receptor antagonists naloxone or β-funaltrexamine (Stone et al., 1997; Tseng et al., 2000a). In the μ-opioid receptor knockout mice or μ-opioid receptor-deficient CXBK mice, neither endomorphin-1 nor endomorphin-2 produce any significant antinociceptive effects (Tseng et al., 1998;Mizoguchi et al., 1999). In [35S]guanosine-5′-O-(3-thio) triphosphate binding assay, neither endomorphin-1 nor endomorphin-2 produce any activation of G protein in the spinal cord (Narita et al., 1998) and in the pons/medulla (Mizoguchi et al., 1999) membrane obtained from the μ-opioid receptor knockout mice. These findings strongly indicate that the μ-opioid receptors play an essential role in mediating endomorphin-1- and endomorphin-2-induced antinociception and G protein activation.

We have previously demonstrated that, like morphine or [d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin, both endomorphin-1 and endomorphin-2 given supraspinally produce their antinociception by the stimulation of μ-opioid receptors, because these antinociceptive effects induced by endomorphin-1 and endomorphin-2 given i.c.v. are blocked by the i.c.v. pretreatment with μ-opioid receptor antagonist β-funaltrexamine. In addition, blockade of α2-adrenoceptors and 5-HT receptors in the spinal cord by i.t. injection of yohimbine and methysergide, respectively, blocks effectively the tail-flick inhibition induced by i.c.v.-administered endomorphin-1 and endomorphin-2. However, the antinociception induced by endomorphin-2 given supraspinally contains additional components, which are mediated by the spinal release of dynorphin A (1–17) acting on κ-opioid receptors and the spinal release of [Met5]enkephalin acting on δ2-opioid receptors in the spinal cord (Ohsawa et al., 2000). This is evidenced by the finding that the tail-flick inhibition induced by i.c.v.-administered endomorphin-2, but not endomorphin-1 is blocked by i.t. pretreatment with antiserum against dynorphin A (1–17) or [Met5]enkephalin or opioid κ- and δ2-receptor antagonist nor-binaltorphimine (nor-BNI) and naltriben (NTB), respectively (Ohsawa et al., 2000). Present studies were then designed to determine whether there are also any differential antinociceptive effects of endomorphin-1 and endomorphin-2 given spinally.

Previous SectionNext Section

Materials and Methods

Animals.

Male ICR mice weighing 25 to 30 g (Charles River Breeding Laboratories, Wilmington, MA) were used for the studies. All experiments were approved by and conformed to the guidelines of the Medical College of Wisconsin Animal Care Committee. Animals were housed five per cage in a room maintained at 22 ± 0.5°C with an alternating 12-h light/dark cycle. Food and water were available ad libitum. Animals were used only once in all experiments.

Drugs and Antisera.

Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2), endomorphin-2 (Tyr-Pro-Phe-Phe-NH2; Zadina et al., 1997), NTB (Portoghese et al., 1992), 7-benzylidene naltrexamine (BNTX;Portoghese, 1991), and nor-BNI were synthesized in H. Nagase's laboratory (Pharmaceutical Research Laboratories, Kamakura, Japan). Another drug used wasd-Phe-Cys-Try-d-Try-Orn-Thr-Phe-Thr-NH2(CTOP; Peninsula Laboratory International, Belmont, CA). The antisera against dynorphin A (1–17), [Met5]enkephalin, [Leu5]enkephalin, and β-endorphin were produced by immunization of male New Zealand White rabbits according to the method described previously and the potencies and the cross-immunoreactivities of these antisera have been characterized (Tseng and Collins, 1993; Tseng et al., 2000a).

Assessment of Antinociceptive Response.

Antinociceptive response was determined with the tail-flick test (D'Amour and Smith, 1941). For the measurement of the latency of the tail-flick response, mice were gently held with one hand with the tail positioned in the apparatus (Model TF6; EMDIE Instrument Co., Maidens, VA) for radiant heat stimulation. The tail-flick response was elicited by applying radiant heat to the dorsal surface of the tail. The intensity of the heat stimulus was adjusted so that the animal flicked its tail within 3 to 5 s. The latency of the tail-flick response was measured before (T0) and at various times after (T1) i.t. injections of endomorphins. The inhibition of the tail-flick response by endomorphins was expressed as a percentage of the maximum possible effect, which was calculated as [(T1 − T0)/(T2 − T0)] × 100, where the cut-off time, T2, was set at 10 s for the tail-flick response.

Intrathecal Injection.

Intrathecal injection was made according to the procedure of Hylden and Wilcox (1980) using a 25-μl Hamilton syringe with a 30-gauge needle. Injection volume was 5 μl. Mice were pretreated i.t. with the selective opioid receptor antagonists nor-BNI 24 h prior to, or CTOP, BNTX, or NTB 10 min prior to i.t. challenge with endomorphins. The doses of the receptor antagonists used in the present study were determined based on the information obtained from the previous studies that these doses of antagonists are sufficient to completely block the antinociception induced by respective selective opioid receptor agonists (Tseng et al., 1997). Antiserum against dynorphin A (1–17), [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin was given 60 min before i.t. administration of the endomorphins (Ohsawa et al., 2000).

Statistical Analysis.

The data are expressed as the mean with S.E.M. Comparisons of data were made with a one-way analysis variance following by the Student's t test (comparisons between two groups) and Bonferroni/Dunn probability test (comparisons between two groups for the positive response rate).

Previous SectionNext Section

Results

Tail-Flick Response to i.t. Administration of Endomorphin-1 and Endomorphin-2.

Groups of mice were injected i.t. with different doses of endomorphin-1 or endomorphin-2, and the tail-flick response was measured 5, 10, 15, and 20 min after injection. Intrathecal injection of endomorphin-1 or endomorphin-2 dose dependently caused an increase of the inhibition of the tail-flick response. The inhibition reached its peaks 5 min after injection, rapidly declined, and returned to the preinjection level 20 min after injection (Fig.1). The duration of the tail-flick inhibition induced by endomorphin-1 and endomorphin-2 was about the same. The dose-response curves of the tail-flick inhibition induced by endomorphin-1 and endorphin-2 observed at 5 min after i.t. injection are shown in Fig. 2. The ED50 values (95% confidence limit) for endomorphin-1 and endorphin-2 for the tail-flick inhibition were estimated to be 1.71 (1.39–2.11) and 3.58 (2.96–4.33), respectively.

Figure 1
View larger version:
Figure 1

Time course of changes in the tail-flick inhibition induced by i.t.-injected endomorphin-1 (A) and endomorphin-2 (B). Groups of mice were administered an i.t. injection of different doses of endomorphin-1 or endomorphin-2, and the tail-flick responses were measured at different times after injection. Each value represents the mean ± S.E. for 10 mice.

Figure 2
View larger version:
Figure 2

Dose-response curves for the inhibition of the tail-flick response induced by i.t. injection of endomorphin-1 and endomorphin-2. Groups of mice were administered an i.t. injection of different doses of endomorphin-1 or endomorphin-2, and the tail-flick responses were measured 5 min after the injection. Each value represents the mean ± S.E. for 10 mice.

Effects of i.t. Pretreatment with CTOP, nor-BNI, BNTX, or NTB on Tail-Flick Inhibition Induced by i.t.-Administered Endomorphin-1 and Endomorphin-2.

The tail-flick inhibition induced by the i.t.-administered endomorphin-1 (10 μg) or endomorphin-2 (10 μg) was significantly attenuated by i.t. pretreatment with 50 ng of CTOP. A higher dose of CTOP (150 ng) almost completely blocked the tail-flick inhibition induced by endomorphin-1 or endomorphin-2 given i.t. Intrathecal pretreatment with nor-BNI (3–30 μg) dose dependently attenuated the inhibition of the tail-flick response induced by i.t.-administered endomorphin-2 (10 μg). However, nor-BNI even at a high dose of 30 μg only partially blocked the endomorphin-2-induced tail-flick inhibition (Fig. 4). On the other hand, the same i.t. pretreatment with nor-BNI (10 and 30 μg) did not significantly affect the tail-flick inhibition induced by i.t.-administered endomorphin-1 (10 μg) (Fig. 3). Intrathecal pretreatment with BNTX (1 μg) or NTB (3 μg) did not block the inhibition of the tail-flick response induced by either endomorphin-1 or endomorphin-2 (10 μg) given i.t. (Figs. 3 and4). The doses of the antagonists used have been previously reported to completely block the antinociception induced by respective selective opioid agonists (Tseng et al., 1997).

Figure 4
View larger version:
Figure 4

Effects of the blockade of μ-, δ1-, δ2-, and κ-opioid receptors by i.t. pretreatment with CTOP, BNTX, NTB, and nor-BNI, respectively, on the inhibition of the tail-flick responses induced by i.t. injection of endomorphin-2. Groups of mice were administered an i.t. injection of nor-BNI (0.1–30 μg) 24 h or CTOP (50 and 150 ng), BNTX (1 μg), or NTB (3 μg) 10 min before i.t. challenge with endomorphin-2 (10 μg). The tail-flick responses were measured 5 min after the injection of endomorphin-2. Each column represents the mean ± S.E. for 10 mice. *P < 0.05; **P < 0.01 compared with the saline-injected mice.

Figure 3
View larger version:
Figure 3

Effects of the blockade of μ-, δ1-, δ2-, and κ-opioid receptors by i.t. pretreatment with CTOP, BNTX, NTB, and nor-BNI, respectively, on the inhibition of the tail-flick responses induced by i.t. injection of endomorphin-1. Groups of mice were administered an i.t. injection of nor-BNI (10 and 30 μg) 24 h or CTOP (50 and 150 ng), BNTX (1 μg), or NTB (3 μg) 10 min before i.t. challenge with endomorphin-1 (10 μg). The tail-flick responses were measured 5 min after the injection of endomorphin-1. Each column represents the mean ± S.E. for 10 mice. *P < 0.05; **P < 0.01 compared with the saline-injected mice.

As shown in Fig. 5A, i.t. pretreatment with nor-BNI (10 μg) did not affect the inhibition of the tail-flick response induced by various doses of endomorphin-1 given i.t. and caused no change of the dose-response curve for the endomorphin-1-induced tail-flick inhibition. However, the same treatment with nor-BNI (10 μg) significantly attenuated the tail-flick inhibition induced by endomorphin-2 given i.t. and caused the shift of the dose-response curve for i.t.-injected endomorphin-2-induced tail-flick inhibition to the right by 2.29-fold (Fig. 5B).

Figure 5
View larger version:
Figure 5

Effects of i.t. pretreatment with 10 μg of nor-BNI on the dose-response curve for the inhibition of the tail-flick responses induced by i.t. injection of endomorphin-1 (A) and endomorphin-2 (B) in the mouse. Groups of mice were administered an i.t. injection of nor-BNI (10 μg) 24 h before i.t. challenge with endomorphin-1 or endomorphin-2. The tail-flick responses were measured 5 min after the injection of endomorphin-1 and endomorphin-2. Each point represents the mean ± S.E. for 10 mice. The potency ratio (95% confidence limit) of i.t.-injected endomorphin-1- and endomorphin-2-induced antinociception in saline-treated group versus nor-BNI-treated group was 1.01 (0.41–2.52) and 2.29 (1.74–3.11), respectively.

Effects of i.t. Pretreatment with Antiserum against Dynorphin A (1–17), [Met5]Enkephalin, [Leu5]Enkephalin, or β-Endorphin on Tail-Flick Inhibition Induced by i.t.-Administered Endomorphin-1 and Endomorphin-2.

Dynorphin A (1–17) has been proposed to be the endogenous opioid ligand for κ-opioid receptors. The finding that antinociception induced by endomorphin-2 was blocked by the κ-opioid receptor antagonist nor-BNI suggests that endomorphin-2 may release dynorphins, which subsequently act on κ-opioid receptor to produce antinociception. The effect of i.t. pretreatment with an antisera against dynorphin A (1–17), [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin on the tail-flick inhibition induced by endomorphin-1 and endomorphin-2 were studied. Intrathecal pretreatment with an antiserum against dynorphin A (1–17) (10–300 μg) dose dependently attenuated the tail-flick inhibition induced by endomorphin-2 (10 μg) (Fig. 7). However, dynorphin A (1–17) antiserum even at a high dose of 300 μg only partially, but significantly, attenuated the endomorphin-2-induced tail-flick inhibition. In contrast, the same i.t. pretreatment with antiserum against dynorphin A (1–17) (100 and 300 μg) did not affect the tail-flick inhibition induced by endomorphin-1 (10 μg) given i.t. (Fig. 6). The tail-flick inhibition induced by endomorphin-1 (10 μg) or endomorphin-2 (10 μg) given i.t. was not affected by i.t. pretreatment with an antiserum against [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin (Figs. 6 and7).

Figure 7
View larger version:
Figure 7

Effects of i.t. pretreatment with antisera against dynorphin A (1–17), [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin on the inhibition of the tail-flick response induced by i.t. injection of endomorphin-2. Groups of mice were administered an i.t. injection of various doses of antiserum against dynorphin A (1–17) (10, 30, 100, and 300 μg) or 100 μg of antiserum against [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin 60 min before i.t. challenge with endomorphin-2 (10 μg), and the tail-flick response was measured 5 min after the injection. NRS, normal rabbit serum; A/S Dyn, antiserum against dynorphin A (1–17); A/S M-Enk antiserum against [Met5]enkephalin; A/S L-Enk, antiserum against Leu-enkephalin; A/S β-End, antiserum against β-endorphin. Each column represents the mean with S.E. for 10 mice. *P < 0.05 compared with the normal rabbit serum-injected control.

Figure 6
View larger version:
Figure 6

Effects of i.t. injection of antisera against dynorphin A (1–17), [Met5]enkephalin, [Leu5]enkephalin, or β-endorphin on inhibition of the tail-flick response induced by i.t.-administered endomorphin-1 (10 μg). Antisera against dynorphin-A (1–17) (100 and 300 μg i.t.), [Met5]enkephalin (100 μg i.t.), [Leu5]enkephalin (100 μg i.t.), or β-endorphin (100 μg i.t.) was injected 60 min before the injection of endomorphin-1. The tail-flick response was measured 5 min after i.t. injection of endomorphin-1. NRS, normal rabbit serum; A/S Dyn, antiserum against dynorphin A (1–17); A/S M-Enk antiserum against [Met5]enkephalin; A/S L-Enk, antiserum against [Leu5]enkephalin; A/S β-End, antiserum against β-endorphin. Each column represents the mean with S.E. for 10 mice.

Previous SectionNext Section

Discussion

We have previously demonstrated that the inhibition of the tail-flick response induced by either endomorphin-1 or endomorphin-2 given i.c.v. is blocked by i.c.v. pretreatment with a selective μ-opioid receptor antagonist β-funaltrexamine, indicating that the antinociception induced by endomorphin-1 and endomorphin-2 given supraspinally is mediated selectively by the stimulation of μ-opioid receptors (Tseng et al., 2000a). Also, blockade of α2-adrenoceptors and 5-HT receptors in the spinal cord by i.t. pretreatment with yohimbine and methysergide, respectively, attenuates the antinociception induced by endomorphin-1 or endomorphin-2, indicating that these two peptides given supraspinally release noradrenaline and 5-HT in the spinal cord for the production of antinociception. In the present study, antinociception induced by either endomorphin-1 or endomorphin-2 injected intrathecally was completely blocked by i.t. pretreatment with CTOP. This finding indicates that the spinally administered endomorphin-1- or endomorphin-2-induced antinociception is also mediated by the stimulation of μ-opioid receptors in the spinal cord. Earlier, Stone et al. (1997) reported that endomorphin-1 or endomorphin-2 given i.t. dose dependently produces antinociception, which is blocked by naloxone given i.t., in the tail-flick test. The importance of μ-opioid receptors for endomorphin-1 and endomorphin-2 to produce antinociception is also supported by our previous studies. Both endomorphin-1 and endomorphin-2 do not activate G proteins in the spinal cord and pons/medulla tissues of the μ-opioid receptor knockout mice (Narita et al., 1998; Mizoguchi et al., 1999) and both peptides given i.c.v. fail to produce any antinociception in μ-opioid receptor knockout mice (Mizoguchi et al., 1999).

However, the antinociception induced by endomorphin-2, but not endomorphin-1, contains an additional component, which is mediated by the stimulation of κ-opioid receptors at the supraspinal and spinal sites. This is evidenced by the findings in our previous studies that the antinociception induced by i.c.v.-administered endomorphin-2, but not endomorphin-1, is blocked by the i.c.v. or i.t. pretreatment with κ-opioid receptor antagonist nor-BNI (Ohsawa et al., 2000; Tseng et al., 2000a). We found in the present study that antinociception induced by endomorphin-2, but not endomorphin-1 given i.t. was also attenuated by i.t. pretreatment with κ-opioid receptor antagonist nor-NBI, indicating the involvement of κ-opioid receptors in the spinal cord for endomorphin-2-induced antinociception. However, nor-BNI even at high doses, which completely blocks the selective κ agonist-induced antinociception (Tseng et al., 1997), only partially, but not entirely, blocked the antinociception induced by endomorphin-2. The finding appears to indicate that the endomorphin-2-induced antinociception is mediated only in part by a κ-opioid receptor mechanism in the spinal cord.

Since endomorphin-2 has a very low affinity for κ-opioid receptors in in vitro receptor binding assay (Zadina et al., 1997), it is unlikely that this endomorphin-2-induced antinociception is due to a direct stimulation of κ-opioid receptors by endomorphin-2. This view is further supported by our previous finding that endomorphin-2 does not activate G proteins with [35S]guanosine-5′-O-(3-thio)triphosphate binding in the spinal cord tissue obtained from μ-opioid receptor knockout mouse, which is still responsive to the κ-opioid receptor agonist for G protein activation (Narita et al., 1999).

Dynorphin A (1–17) has been proposed to be a neurotransmitter for κ-opioid receptors. The possibility that i.t.-administered endomorphin-2-induced antinociception is mediated by the spinal release of dynorphin A (1–17), which subsequently stimulates κ-opioid receptors for producing antinociception, was then explored. It was found that i.t. pretreatment with an antiserum against dynorphin A (1–17) attenuated the antinociception induced by i.t.-injected endomorphin-2, but not endomorphin-1. The results of the present study are also consistent with our previous finding that the antinociception induced by endomorphin-2 given i.c.v. was also attenuated by i.c.v. pretreatment with antiserum against dynorphin A (1–17) (Tseng et al., 2000a), indicating that antinociception induced by endomorphin-2 given either supraspinally or spinally is mediated by the same dynorphinergic mechanism. Thus, activation of μ-opioid receptors by endomorphin-2 initially induces the release of dynorphin A (1–17), which subsequently acts on κ-opioid receptors for the production of antinociception. We propose that there are two subtypes of μ-opioid receptors that are involved in endomorphin-1- and endomorphin-2-induced antinociception. One subtype of μ-opioid receptors is stimulated by both endomorphin-1 and endomorphin-2 and another subtype of μ-opioid is solely stimulated by endomorphin-2 and is involved in the release of dynorphin A (1–17) acting on κ-opioid receptors for the production of antinociception.

The antinociception induced by i.c.v.-injected endomorphin-2 also contains another component, which is mediated by the spinal release of [Met5]enkephalin acting on δ2-opioid receptors in the spinal cord. This view is supported by the finding that i.t. pretreatment with antiserum against [Met5]enkephalin or δ2-opioid receptor antagonist NTB attenuated the tail-flick inhibition induced by endomorphin-2 given i.c.v. (Ohsawa et al., 2000). However, we found in the present study that i.t. pretreatment with antiserum against [Met5]enkephalin or NTB failed to affect the tail-flick inhibition induced by endomorphin-2 given i.t., indicating that [Met5]enkephalin and δ2-opioid receptors in the spinal cord are not involved in spinally administered endomorphin-2-induced antinociception.

Others from different laboratories also reported the different antinociceptive effects induced by endomorphin-1 and endomorphin-2. Systemic pretreatment with μ1-opioid receptor antagonist naloxonazine attenuates the antinociception induced by endomorphin-2, but not endomorphin-1 given i.t. or i.c.v., suggesting that antinociception induced by endomorphin-2, but not endomorphin-1 is mediated by the stimulation of naloxonazine-sensitive μ-opioid receptors (Sakurada et al., 1999, 2000). Pretreatment with different antisense oligodeoxynucleotides (ODNs) against different G protein subunits was also able to differentiate antinociceptive effects induced by endomorphin-1 and endomorphin-2. Intrathecal pretreatment with antisense ODN against G protein subunit Giα2 protein attenuates the antinociception induced by i.t.-administered endomorphin-2, but not endomorphin-1, while i.t. pretreatment with antisense ODN against G protein subunits of Giα1, Giα3, or Gzα does not affect the antinociception induced by either endomorphin-1 or endomorphin-2 (Sánchez-Blázquez et al., 1999). It is most likely that the differential antinociceptive effects observed are mediated by the stimulation of different subtypes of μ-opioid receptors.

In conclusion, the antinociception induced by both endomorphin-1 and endomorphin-2 given spinally is mediated by the stimulation of μ-opioid receptors in the spinal cord. However, endomorphin-2-induced antinociception also contains an additional component, which is mediated by the release of dynorphin A (1–17) acting on κ-opioid receptors in the spinal cord. It is most likely that different subtypes of μ-opioid receptors are involved in endomorphin-1- and endomorphin-2-induced antinociception in the spinal cord.

Previous SectionNext Section

Footnotes

  • This study was supported by Grant DA 03811 from the National Institutes of Health, National Institute on Drug Abuse (to L.F.T.). A preliminary report of some of these results was presented at the 30th Annual Meeting of the Neuroscience, New Orleans, LA, November 4–9, 2000 (Tseng et al., 2000b).

  • Abbreviations:
    i.t.
    intrathecal
    5-HT
    5-hydroxytryptamine
    nor-BNI
    nor-binaltorphimine
    NTB
    naltriben
    BNTX
    7-benzylidene naltrexamine
    CTOP
    d-Phe-Cys-Tyr-d-Try-Orn-Thr-Pen-Thr-NH2
    ODN
    oligodeoxynucleotide
    • Received January 26, 2001.
    • Accepted April 18, 2001.
Previous Section
 

References

  1. ↵
    1. D'Amour FE,
    2. Smith DL
    (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79.
    Abstract/FREE Full Text
  2. ↵
    1. Goldberg IE,
    2. Rossi GC,
    3. Letchworth SR,
    4. Mathis JP,
    5. Ryan-Moro J,
    6. Leventhal L,
    7. Su W,
    8. Emmel D,
    9. Bolan EA,
    10. Pasternak GW
    (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286:1007–1013.
    Abstract/FREE Full Text
  3. ↵
    1. Hylden JLK,
    2. Wilcox GL
    (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 167:313–316.
  4. ↵
    1. Martin-Schild S,
    2. Gerall AA,
    3. Kastin AJ,
    4. Zadina JE
    (1998) Endomorphin-2 is an endogenous opioid in the primary sensory afferent fibers. Peptides 19:1783–1789.
    CrossRefMedline
  5. ↵
    1. Martin-Schild S,
    2. Gerall AA,
    3. Kastin AJ,
    4. Zadina JE
    (1999) Differential distribution of endomorphin-1- and endomorphin-2-like immunoreactivities in the CNS of the rodent. J Comp Neurol 405:450–471.
    CrossRefMedlineWeb of Science
  6. ↵
    1. Martin-Schild S,
    2. Zadina JE,
    3. Gerall AA,
    4. Vigh S,
    5. Kastin AJ
    (1997) Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides 18:1641–1649.
    CrossRefMedlineWeb of Science
  7. ↵
    1. Mizoguchi H,
    2. Narita M,
    3. Oji DE,
    4. Suganuma C,
    5. Nagase H,
    6. Sora I,
    7. Uhl GR,
    8. Cheng EY,
    9. Tseng LF
    (1999) The μ-opioid receptor gene dose-dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in μ-opioid receptor knockout mice. Neuroscience 94:203–207.
    CrossRefMedline
  8. ↵
    1. Narita M,
    2. Mizoguchi H,
    3. Narita M,
    4. Sora I,
    5. Uhl GR,
    6. Tseng LF
    (1999) Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord form mu-opioid receptor knockout mice. Br J Pharmacol 126:451–456.
    CrossRefMedline
  9. ↵
    1. Narita M,
    2. Mizoguchi H,
    3. Oji GE,
    4. Tseng EL,
    5. Suganuma C,
    6. Nagase H,
    7. Tseng LF
    (1998) Characterization of endomorphin-1 and -2 on [35S]GTPγS binding in the mouse spinal cord. Eur J Pharmacol 351:383–387.
    CrossRefMedlineWeb of Science
  10. ↵
    1. Ohsawa M,
    2. Mizoguchi H,
    3. Narita M,
    4. Chu M,
    5. Nagase H,
    6. Tseng LF
    (2000) Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 294:1106–1111.
    Abstract/FREE Full Text
  11. ↵
    1. Pierce TL,
    2. Grahek MD,
    3. Wessendorf MW
    (1998) Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport 9:385–389.
    MedlineWeb of Science
  12. ↵
    1. Portoghese PS
    (1991) An approach to the design of receptor-type selective nonpeptide antagonists of peptidergic receptors: δ opioid antagonists. J Med Chem 34:1757–1762.
    CrossRefMedline
  13. ↵
    1. Portoghese PS,
    2. Sultana M,
    3. Nagase H,
    4. Takemori AE
    (1992) A highly selective δ1-opioid receptor antagonist: 7-benzylidene naltrexamine. Eur J Pharmacol 218:195–196.
    CrossRefMedlineWeb of Science
  14. ↵
    1. Sakurada S,
    2. Hayashi T,
    3. Yuhki M,
    4. Fujimura T,
    5. Maruyama K,
    6. Yonezawa A,
    7. Sakurada C,
    8. Takeshita M,
    9. Zadina JE,
    10. Kastin AJ,
    11. et al.
    (2000) Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone. Brain Res 881:1–8.
    CrossRefMedlineWeb of Science
  15. ↵
    1. Sakurada S,
    2. Zadina JE,
    3. Kastin AJ,
    4. Katsuyama S,
    5. Fujimura T,
    6. Murayama K,
    7. Yuki M,
    8. Ueda H,
    9. Sakurada T
    (1999) Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. Eur J Pharmacol 372:25–30.
    CrossRefMedline
  16. ↵
    1. Sánchez-Blázquez P,
    2. Rodrı́guez-Dı́az M,
    3. Deantonio I,
    4. Garzón J
    (1999) Endomorphin-1 and endomorphin-2 show differences in their activation of μ opioid receptor regulated G-proteins in supraspinal antinociception in mice. J Pharmacol Exp Ther 291:12–18.
    Abstract/FREE Full Text
  17. ↵
    1. Schreff M,
    2. Schulz S,
    3. Wiborny D,
    4. Hollt V
    (1998) Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. Neuroreport 9:1031–1034.
    MedlineWeb of Science
  18. ↵
    1. Stone LS,
    2. Fairbanks CA,
    3. Laughlin TM,
    4. Nguyen HO,
    5. Bushy TM,
    6. Wessendorf MW,
    7. Wilcox GL
    (1997) Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8:3131–3135.
    MedlineWeb of Science
  19. ↵
    1. Tseng LF,
    2. Collins KA
    (1993) Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse. J Pharmacol Exp Ther 266:1430–1438.
    Abstract/FREE Full Text
  20. ↵
    1. Tseng LF,
    2. Narita M,
    3. Mizoguchi H,
    4. Kawai K,
    5. Mizusuna A,
    6. Kamei J,
    7. Suzuki T,
    8. Nagase H
    (1997) Delta-1 opioid receptor-mediated antinociceptive properties of nonpeptidec delta opioid receptor agonist, (−)TAN-67, in the mouse spinal cord. J Pharmacol Exp Ther 280:600–605.
    Abstract/FREE Full Text
  21. ↵
    1. Tseng LF,
    2. Narita M,
    3. Suganuma C,
    4. Mizoguchi H,
    5. Ohsawa M,
    6. Nagase H,
    7. Kampine JP
    (2000a) Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292:576–583.
    Abstract/FREE Full Text
  22. ↵
    1. Tseng LF,
    2. Ohsawa M,
    3. Mizoguchi H,
    4. Narita M,
    5. Nagase H,
    6. Suzuki T
    (2000b) Differential mechanisms mediating antinociception induced by spinally administered endomorphin-1 and -2 in the mouse spinal cord. Soc Neurosci Abstr 26:2189.
  23. ↵
    1. Tseng LF,
    2. Suganuma C,
    3. Narita M,
    4. Oji GS,
    5. Tseng EL,
    6. Bhaita A,
    7. Mizoguchi H,
    8. Nagase H
    (1998) Differential mechanism mediating antinociception induced by supraspinally administered newly discovered endogenous opioid peptides endomorphin-1 and endomorphin-2 in the mouse. Soc Neurosci Abstr 24:1356.
  24. ↵
    1. Zadina JE,
    2. Hackler L,
    3. Ge L-J,
    4. Kastin AJ
    (1997) A potent and selective endogenous agonist for the μ-opioid receptor. Nature (Lond) 386:499–502.
    CrossRefMedline
« Previous | Next Article »Table of Contents

This Article

  1. JPET August 1, 2001 vol. 298 no. 2 592-597
  1. AbstractFree
  2. » Full Text
  3. Full Text (PDF)

Classifications

Responses

  1. Submit a response
  2. No responses published

Navigate This Article

Current Issue

  1. November 2009, 331 (2)
  1. Current Issue
  1. Alert me to new issues of JPET